I am a supramolecular polymer chemist and my researches focus on biomedical engineering including drug delivery system (nanovalves), nanosensor, nanophotonics, tribology and cell mechanics.

I am the Communications and Digital Platforms Associate at FEBS, and I help manage content and use of online platforms and sites such as the FEBS Network, FEBS website and FEBS Congress website, but particularly on the FEBS Network. Previously I have managed the funding programmes of a number of UK research charities, mainly in the field of cancer. I have supported the income generation teams at those organisations with science communication, as well as developed e-learning resources for staff and students at the Institute of Cancer Research. I have a BSc in Biochemistry, an MSc in Nutrition and a Postgraduate Diploma in Dietetics. After years in London I have now moved back to Spain, where I continue to work as a science communicator.

Nanotechnology, drug delivery systems, biosensors, chromatography, advanced materials characterization

iam graduated from faculty of science, chemistry and biochemistry dep. i have a biomedical analysis diploma. my master degree focused in treatment diabetes with the combination therapy using natural products and a pharmaceutical. i hope to find a PHD position in biochemistry. mainly my interest in biochemistry. title of thesis( treatment of HFD induced diabetes with combination of metformin and natural products)

The Spanish Society for Biochemistry and Molecular Biology (SEBBM) was founded in 1963, currently has more than 3370 members and is the main scientific society that coordinates activities in Spain related to the extensive field of Biochemistry and Molecular Biology. SEBBM protector members: Bio-Rad, Eppendorf, Fisher Scientific, Control Técnica, Waldner, Merck, ASEBIO and Promega.

Dr. Isabel Varela-Nieto graduated and earned her doctorate in Chemistry, Biochemistry Section, at the University Complutense of Madrid (Spain). She has been a visiting guest scientist at the Medical Schools of Uppsala (FEBS Fellow, Sweden) and San Diego (MEC Sabbatical, USA). She is Professor of Research at the CSIC and group leader at the CIBER of rare diseases (CIBERER, ISCIII) in Madrid. From the early 1990s she has been studying hearing neurobiology and IGF-1 actions. She was the first Chair of the SEBBM Science for Society working group with which she actively collaborates, and member of the FEBS Network working group. She is currently the president of the SEBBM, a member of the FEBS Science and Society Committee and of the ISC Finances Committee.